Allogene Therapeutics (ALLO) Equity Ratio (2018 - 2026)

Allogene Therapeutics has disclosed Equity Ratio across 9 years of filings, most recently posting 0.7 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.7, down 7.17% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.7 (down 7.17% YoY), and the FY2025 annual result was 0.7, down 8.58% from the prior year.
• Equity Ratio came in at 0.7 for Q1 2026 at Allogene Therapeutics, roughly flat from 0.7 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.88 in Q1 2022 to a low of 0.7 in Q4 2025.
• The 5-year median for Equity Ratio is 0.79 (2023), against an average of 0.78.
• Across the five-year window, Equity Ratio fell 10.79% in 2023 and retreated 0.3% in 2024, its largest moves.
• Allogene Therapeutics' Equity Ratio stood at 0.81 in 2022, then dropped by 1.83% to 0.8 in 2023, then declined by 3.44% to 0.77 in 2024, then fell by 8.58% to 0.7 in 2025, then climbed by 0.13% to 0.7 in 2026.
• The last three Equity Ratio figures came in at 0.7 (Q1 2026), 0.7 (Q4 2025), and 0.72 (Q3 2025), per Business Quant data.